

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6626494

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NEXION BIOSCIENCES INC.	11/12/2020
RECEIVING PARTY DATA	
Name:	GENVOR INC.
Street Address:	13155 NOEL ROAD, STE. 900
City:	DALLAS
State/Country:	TEXAS
Postal Code:	75240
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	62764430
Application Number:	62764431
Application Number:	16134336
CORRESPONDENCE DATA	
Fax Number:	(214)866-0010
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2148660001
Email:	kthiesse@chalkerflores.com
Correspondent Name:	EDWIN FLORES C/O CHALKER FLORES LLP
Address Line 1:	14951 NORTH DALLAS PARKWAY, SUITE 400
Address Line 4:	DALLAS, TEXAS 75254
ATTORNEY DOCKET NUMBER:	GENV:1001
NAME OF SUBMITTER:	KAREN THIESSE
SIGNATURE:	/KAREN THIESSE/
DATE SIGNED:	03/29/2021
Total Attachments: 2	
source=GENV1001_corr_Ex Assignment Nexion to Genvor#page1.tif	
source=GENV1001_corr_Ex Assignment Nexion to Genvor#page2.tif	

PATENT ASSIGNMENT

WHEREAS, an Assignment of Patent and/or Patent Application Rights of the patent applications listed below from Nexion Corporation to Nexion LLC was executed on January 22, 2019 and recorded with the USPTO at Reel 048201, Frame 0540 on January 31, 2019 (hereinafter referred to as the "2019 Assignment");

0539

WHEREAS, the patent applications listed below were filed listing Nexion Biosciences Inc. as the assignee;

WHEREAS, the 2019 Assignment incorrectly listed Nexion Corporation as the assignor and Nexion LLC as the assignee;

WHEREAS, the correct entities in the 2019 Assignment were Nexion Biosciences Inc. as assignor and Nexion Biosciences LLC as assignee;

WHEREAS, the name of Nexion Biosciences Inc. was changed to Genvor Inc. on January 22, 2020 (hereinafter referred to as the "2020 Nexion Name Change"); and

WHEREAS, Nexion Biosciences Inc. and Nexion Biosciences LLC desire that Genvor Inc. own the patent applications listed below.

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, Nexion Biosciences LLC, does hereby sell, assign and transfer to Genvor Inc. any and all rights, title and interest, including all existing, future and/or expected rights, in and to any and all inventions, subject matter and improvements disclosed in the patent applications listed below, any and all divisional, continuing, substitute, renewal, reissue or other applications for patent which have been or will be filed in any country based on the patent applications listed below, any and all original, reissued or reexamined patents which have been or will be issued in any country based on the patent applications listed below, and the right to file patent applications based on the patent applications listed below in any country:

U.S. Patent Application No. 62/764,430 filed on August 2, 2018 and entitled "Peptides with Potent Antimicrobial Activity";

U.S. Patent Application No. 62/764,431 filed on August 2, 2018 and entitled "Proteins for Improving the Nutritional Value of Food and Feed Crops"; and

U.S. Patent Application No. 16/134,336 filed on September 18, 2018 and entitled "Transgenic Corn with Antifungal Peptide AGM182 USDA (DN:0113.18).

In the event, the assignment of the patent applications listed above from Nexion Biosciences Inc. to Nexion Biosciences LLC in the 2019 Assignment as corrected above is ineffective, or the above assignment of the patent applications from Nexion Biosciences LLC to Genvor Inc. is ineffective, Nexion Biosciences Inc. does agree and acknowledge that Genvor Inc., owns any and all rights, title and interest, including existing, future and/or expected rights, in and to any and all inventions, subject matter and improvements disclosed in the patent applications listed above, any and all divisional, continuing, substitute, renewal, reissue or other applications for patent which have been or will be filed in any country based on the patent applications listed above, any and all original, reissued or reexamined patents which have been or will be issued in any country based on the patent applications listed above, and the right to file patent

applications based on the patent applications listed above in any country by virtue of the 2020 Nexion Name Change.

IN WITNESS WHEREOF, I have hereunto signed my name on the day and year set forth below.

NEXION BIOSCIENCES INC.

Signature:



Name: Brad White

Date: 11.12.2020

NEXION BIOSCIENCES LLC.

Signature:



Name: Brad White

Date: 11.12.2020

GENVOR INC.

Signature:



Name: Brad White

Date: 11.12.2020